[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623492":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":35,"centralContacts":58,"locations":64,"responsibleParty":158,"collaborators":160,"id":163,"slug":164,"hasResults":165,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":35,"eligibilityCriteria":169,"healthyVolunteers":165,"sex":170,"minAge":171,"maxAge":35,"enrollmentInfo":172,"targetDuration":35,"studyType":175,"phases":176,"briefSummary":179,"conditions":180,"keywords":187,"overallStatus":67,"whyStopped":35,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},{"fullName":5,"class":6},"Revolution Medicines, Inc.","INDUSTRY",[8,16,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: Daraxonrasib + Ivonescimab Combination","EXPERIMENTAL","Dose Exploration and Dose Expansion (+ Carboplatin\u002FCisplatin + Pemetrexed)",[13,14,15],"Drug: Daraxonrasib","Drug: Ivonescimab","Drug: Carboplatin\u002FCisplatin + Pemetrexed (Dose Expansion Only)",{"label":17,"type":10,"description":18,"interventionNames":19},"Arm B: Elironrasib + Ivonescimab Combination","Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort B1 (+ daraxonrasib) and Cohort B2 (+ Carboplatin\u002FCisplatin + Pemetrexed).",[20,14,21,22],"Drug: Elironrasib","Drug: Carboplatin\u002FCisplatin + Pemetrexed (Cohort B2 Only)","Drug: Daraxonrasib (Cohort B1 only)",{"label":24,"type":10,"description":25,"interventionNames":26},"Arm C: Zoldonrasib + Ivonescimab Combination","Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort C1 and Cohort C2 (+ Cetuximab).",[27,14,28],"Drug: Zoldonrasib","Drug: cetuximab (Cohort C2 Only)",[30,36,39,42,46,49,52,55],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","Daraxonrasib","oral tablets",[9],null,{"type":31,"name":37,"description":33,"armGroupLabels":38,"otherNames":35},"Elironrasib",[17],{"type":31,"name":40,"description":33,"armGroupLabels":41,"otherNames":35},"Zoldonrasib",[24],{"type":31,"name":43,"description":44,"armGroupLabels":45,"otherNames":35},"Ivonescimab","IV infusion",[9,17,24],{"type":31,"name":47,"description":44,"armGroupLabels":48,"otherNames":35},"Carboplatin\u002FCisplatin + Pemetrexed (Dose Expansion Only)",[9],{"type":31,"name":50,"description":44,"armGroupLabels":51,"otherNames":35},"cetuximab (Cohort C2 Only)",[24],{"type":31,"name":53,"description":44,"armGroupLabels":54,"otherNames":35},"Carboplatin\u002FCisplatin + Pemetrexed (Cohort B2 Only)",[17],{"type":31,"name":56,"description":33,"armGroupLabels":57,"otherNames":35},"Daraxonrasib (Cohort B1 only)",[17],[59],{"name":60,"role":61,"phone":62,"phoneExt":35,"email":63},"Revolution Medicines Study Director","CONTACT","1-844-2-REVMED","medinfo@revmed.com",[65,85,100,115,129,143],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Eastern Connecticut Hematology and Oncology Associates","RECRUITING","Norwich","Connecticut","06360","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-72.07591,41.52426,{"lat":77,"lon":76},[80],{"name":81,"role":61,"phone":82,"phoneExt":83,"email":84},"Spiro Curis","860-886-8362","ext 251","Scuris@echoct.com",{"facility":86,"status":67,"city":87,"state":88,"zip":89,"country":71,"countryCode":72,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Tennessee Oncology","Nashville","Tennessee","37023",{"type":74,"coordinates":91},[92,93],-86.78444,36.16589,{"lat":93,"lon":92},[96],{"name":97,"role":61,"phone":98,"phoneExt":35,"email":99},"Kathryn Capps","615-879-6410","Kathryn.capps@thonc.com",{"facility":101,"status":67,"city":102,"state":103,"zip":104,"country":71,"countryCode":72,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":74,"coordinates":106},[107,108],-95.36327,29.76328,{"lat":108,"lon":107},[111],{"name":112,"role":61,"phone":113,"phoneExt":35,"email":114},"Ly Nguyen","832-794-3672","LMNguyen1@mdanderson.org",{"facility":116,"status":67,"city":117,"state":103,"zip":118,"country":71,"countryCode":72,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"NEXT Dallas","Irving","75039",{"type":74,"coordinates":120},[121,122],-96.94889,32.81402,{"lat":122,"lon":121},[125],{"name":126,"role":61,"phone":127,"phoneExt":35,"email":128},"Mofopefoluwa \"Fope\" Akinwale","972-893-8800","fakinwale@nextoncology.com",{"facility":130,"status":67,"city":131,"state":103,"zip":132,"country":71,"countryCode":72,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"NEXT Oncology","San Antonio","78229",{"type":74,"coordinates":134},[135,136],-98.49363,29.42412,{"lat":136,"lon":135},[139],{"name":140,"role":61,"phone":141,"phoneExt":35,"email":142},"Jordan Georg","210-580-9521","jgeorg@nextoncology.com",{"facility":144,"status":67,"city":145,"state":146,"zip":147,"country":71,"countryCode":72,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"NEXT Virginia","Fairfax","Virginia","22031",{"type":74,"coordinates":149},[150,151],-77.30637,38.84622,{"lat":151,"lon":150},[154],{"name":155,"role":61,"phone":156,"phoneExt":35,"email":157},"Maybelle De La Rosa","703-783-4518","mdelarosa@nextoncology.com",{"type":159,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[161],{"name":162,"class":6},"Summit Therapeutics","100623492","phase-1-study-of-rason-inhibitors-in-combination-with-ivonescimab-in-patients-with-solid-tumors-100623492",false,"NCT07397338","Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","A Phase 1\u002F2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.\n* Received and progressed or been intolerant to prior standard therapy (Part 1 Dose Exploration).\n* Non-squamous NSCLC without a treatable driver mutation in other oncogenes that has not received prior systemic treatment (Arms A \\& B for Part 2 Dose Expansion).\n* Solid tumor or CRC previously treated with no more than 2 prior lines of therapy for advanced disease and progressed or been intolerant to prior standard therapies (Arm C for Part 2 Dose Expansion).\n* Measurable disease per RECIST v1.1\n* Adequate organ function (bone marrow, liver, kidney, coagulation, endocrine).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Head and neck squamous cell carcinoma.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 4 weeks prior to receiving study drug(s).\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.\n* Other inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":173,"type":174},370,"ESTIMATED","INTERVENTIONAL",[177,178],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.",[181,182,183,184,185,186],"Advanced Solid Tumors","Metastatic Solid Tumors","Non-small Cell Lung Cancer (NSCLC)","NSCLC","Colorectal Cancer (CRC)","CRC",[181,182,188,184,189,186,190,191,192,193,194],"Non-small Cell Lung Cancer","Colorectal Cancer","RAS","NRAS","KRAS","HRAS","RAS Mutation","2026-06-26",{"date":197,"type":198},"2026-06-29","ACTUAL",{"date":200,"type":198},"2026-01-30",{"date":202,"type":174},"2029-05",{"name":5,"class":6},6]